ADAPTIMMUNE THERAPEUTICS PLC

Analyst Reco. Adaptimmune Therapeutics plc

Equities

ADAP

US00653A1079

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.075 ^USD	+1.42%		+10.06%	+35.56%

Apr. 24	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT
Apr. 23	European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Barclays Adjusts Adaptimmune Therapeutics Price Target to $1 From $2, Maintains Underweight Rating	23-08-10	MT
EF Hutton Initiates Adaptimmune Therapeutics at Buy With $10 Price Target	23-01-05	MT
Guggenheim Upgrades Adaptimmune Therapeutics to Buy From Neutral, Price Target is $5	23-01-03	MT
Wells Fargo Adjusts Price Target on Adaptimmune Therapeutics to $3 From $1.50, Maintains Equal-Weight Rating	22-11-14	MT
Mizuho Upgrades Adaptimmune Therapeutics to Buy From Neutral, Price Target is $9	22-11-09	MT
SVB Leerink Adjusts Adaptimmune Therapeutics' Price Target to $3 from $7, Keeps Market Perform Rating	22-03-15	MT
Barclays Cuts Price Target for Adaptimmune Therapeutics to $2 From $4, Maintains Underweight Rating	22-03-14	MT
ADAPTIMMUNE THERAPEUTICS : Wells Fargo Adjusts Price Target on Adaptimmune Therapeutics to $7 From $6, Maintains Equal-Weight Rating	21-09-22	MT
ADAPTIMMUNE THERAPEUTICS : SVB Leerink Adjusts Adaptimmune Therapeutics PT to $7 From $6, Maintains Market Perform Rating	21-09-13	MT
Adaptimmune Therapeutics plc Announces Clinical Responses Across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation Surpass Trial	21-09-13	CI
ADAPTIMMUNE THERAPEUTICS : SVB Leerink Adjusts Adaptimmune Therapeutics' Price Target to $6 from $5, Keeps Market Perform Rating	21-09-07	MT
ADAPTIMMUNE THERAPEUTICS : Barclays Starts Adaptimmune Therapeutics at Underweight With $4 Price Target	21-05-28	MT
ADAPTIMMUNE THERAPEUTICS : SVB Leerung Adjusts Adaptimmune Therapeutics PT to $6 From $10, Maintains Market Perform Rating	20-11-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer